LEIDEN, Netherlands, April 05, 2005 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) today announced that it will release its financial results for the first quarter of 2005 on Monday, April 18, 2005 at 14:00 p.m. Central European Time (CET) (8:00 a.m. U.S. Eastern Standard Time).
Thirty minutes later, at 14:30 p.m. CET, Crucell will conduct a conference call open to all, which will also be webcast. To participate in the conference call, please call one of the following toll-free numbers 10 minutes prior to commencement:
888-408-5523 for the US;
0800-358-5269 for the UK; and
0800-265-8531 for the Netherlands.
Following a presentation of the results you will be able to ask questions during a question and answer session.
The live audio webcast can be accessed via the homepage of Crucell's website at www.crucell.com, and will be archived and available for replay from 18:00 p.m. CET for two weeks following the event.
About Crucell
Crucell N.V. is a biotechnology company focused on developing vaccines and antibodies that prevent and treat infectious diseases, including Ebola, influenza, malaria, West Nile virus and rabies. The company's development programs include collaborations with sanofi pasteur for influenza vaccines, the U.S. National Institutes of Health for Ebola and malaria vaccines, and GlaxoSmithKline (GSK), Walter Reed Army Institute of Research and New York University for a malaria vaccine. Crucell's products are based on its innovative PER.C6(R) technology, which offers a safer, more efficient way to produce biopharmaceuticals. The company licenses its PER.C6(R) technology to the biopharmaceutical industry on a mostly non-exclusive basis. Licensees and partners include DSM Biologics, GSK, Centocor/J&J and Merck & Co., Inc. Crucell is headquartered in Leiden, The Netherlands, and is listed on the Euronext and NASDAQ stock exchanges (ticker symbol CRXL). For more information, please visit www.crucell.com.
This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on February 27, 2004, and the section entitled "Risk Factors". The company prepares its financial statements under generally accepted accounting principles in the United States (US GAAP).
Click here for a PDF version of this press release: http://hugin.info/132631/R/987708/147750.pdf
-0- For further information please contact: Crucell N.V. Leon Kruimer, Chief Financial Officer Tel. +31 (0)71 524 8722 l.kruimer@crucell.com For Crucell N.V. in the USA: Redington Inc. Thomas Redington Tel. +1 212-926-1733 tredington@redingtoninc.com